^
    Apply
    Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) (NCT06052618)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    01/01/2033
    Completion :
    01/01/2034
    CRP
    |
    Vonjo (pacritinib)
    Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    11/22/2021
    Primary completion :
    11/02/2025
    Completion :
    11/02/2025
    CD276 • VTCN1 • CD4 • HHLA2
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma (NCI-2018-02529) (NCT03316274)
    Phase 1
    University of California, San Francisco
    Completed
    Last update posted :
    06/25/2024
    Initiation :
    05/07/2018
    Primary completion :
    06/30/2021
    Completion :
    06/30/2021
    PD-L1 • IFNG • CD4
    |
    PD-L1 expression • PD-1 expression
    |
    Opdivo (nivolumab)
    NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma (NCT04303117)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    07/13/2020
    Primary completion :
    09/01/2025
    Completion :
    12/01/2028
    CD4
    |
    pomalidomide • bintrafusp alfa (M7824) • PDS01ADC
    A Study of sEphB4-HSA in Kaposi Sarcoma (NCT03993106)
    Phase 2
    Vasgene Therapeutics, Inc
    Recruiting
    Last update posted :
    05/02/2024
    Initiation :
    09/17/2020
    Primary completion :
    12/01/2024
    Completion :
    06/01/2025
    CD4
    |
    sEphB4-HSA
    Pomalidomide Treatment in Patients With Kaposi Sarcoma (NCT04577755)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    03/18/2022
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    CD4
    |
    pomalidomide
    Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02408861)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    10/21/2015
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    CD8 • IFNG • CD4
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (NCT05859074)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/15/2024
    Initiation :
    05/04/2023
    Primary completion :
    05/04/2028
    Completion :
    05/04/2028
    BRAF
    |
    PD-L1 expression • BRAF mutation
    |
    Keytruda (pembrolizumab) • MQ710
    Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    11/03/2023
    Initiation :
    04/04/2016
    Primary completion :
    10/04/2023
    Completion :
    10/11/2024
    PD-L1 • BRAF • ALK • ROS1 • CD4
    |
    BRAF V600 • ALK mutation • ROS1 mutation
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma (STARKAP) (NCT05646082)
    Phase 1
    Imperial College London
    Recruiting
    Last update posted :
    08/10/2023
    Initiation :
    05/26/2023
    Primary completion :
    05/01/2024
    Completion :
    09/01/2025
    CD4
    |
    Jemperli (dostarlimab-gxly)
    sEphB4-HSA in Treating Patients With Kaposi Sarcoma (NCT02799485)
    Phase 2
    AIDS Malignancy Consortium
    Recruiting
    Last update posted :
    06/27/2023
    Initiation :
    02/13/2018
    Primary completion :
    03/31/2024
    Completion :
    04/30/2024
    EPHB4
    |
    sEphB4-HSA